Back to Journals » Psoriasis: Targets and Therapy » Volume 11 » default
Psoriasis: Targets and Therapy
ISSN: 2230-326X
- View all (141)
- Volume 14, 2024 (8)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Archive: Volume 11, 2021
The Use of Metrics in Daily Practice and the Perception of Psoriasis-Associated Comorbidities: Discrepancies Between Research and Real-World
Hillary T, Lambert J
Psoriasis: Targets and Therapy 2021, 11:169-175
Published Date: 21 December 2021
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Balak DMW, Piaserico S, Kasujee I
Psoriasis: Targets and Therapy 2021, 11:151-168
Published Date: 7 December 2021
High-Throughput RNA Sequencing Reveals the Effect of NB-UVB Phototherapy on Major Inflammatory Molecules of Lesional Psoriasis
Vacharanukrauh P, Meephansan J, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, Serirat O, Komine M
Psoriasis: Targets and Therapy 2021, 11:133-149
Published Date: 26 November 2021
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
Hampton P, Borg E, Hansen JB, Augustin M
Psoriasis: Targets and Therapy 2021, 11:123-131
Published Date: 3 November 2021
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P
Psoriasis: Targets and Therapy 2021, 11:109-122
Published Date: 14 August 2021
Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
Teklu M, Parel PM, Mehta NN
Psoriasis: Targets and Therapy 2021, 11:99-108
Published Date: 21 July 2021
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Ben Abdallah H, Johansen C, Iversen L
Psoriasis: Targets and Therapy 2021, 11:83-97
Published Date: 29 June 2021
An Association of Pediatric Psoriasis with Metabolic Syndrome in Thai Children: 20 Years Retrospective Study
Mhusakunchai P, Techasatian L
Psoriasis: Targets and Therapy 2021, 11:75-82
Published Date: 29 June 2021
Updates on the Treatment of Erythrodermic Psoriasis
Lo Y, Tsai TF
Psoriasis: Targets and Therapy 2021, 11:59-73
Published Date: 9 June 2021
Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
Chan Y, Tong BSB, Ngan PY, Au CS
Psoriasis: Targets and Therapy 2021, 11:53-58
Published Date: 1 June 2021
Association of HLA Alleles and HLA Haplotypes with Psoriasis, Psoriatic Arthritis and Disease Severity in a Miscegenated Population
Cassia FF, Cardoso JF, Porto LC, Ramos-e-Silva M, Carneiro S
Psoriasis: Targets and Therapy 2021, 11:41-51
Published Date: 10 May 2021
Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia
Santos-Moreno P, Gómez-De la Rosa F, Parra-Padilla D, Alvis-Zakzuk NJ, Alvis-Zakzuk NR, Carrasquilla-Sotomayor M, Valencia O, Alvis-Guzmán N
Psoriasis: Targets and Therapy 2021, 11:31-39
Published Date: 18 March 2021
Phosphodiesterase-4 Inhibition in Psoriasis
Milakovic M, Gooderham MJ
Psoriasis: Targets and Therapy 2021, 11:21-29
Published Date: 17 March 2021
Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
Haulrig MB, Zachariae C, Skov L
Psoriasis: Targets and Therapy 2021, 11:1-20
Published Date: 11 February 2021